323 related articles for article (PubMed ID: 20139798)
21. Lopinavir exposure with an increased dose during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli E; Hu C; Burchett SK; Holland DT; Smith E; Gaddipati S; Read JS;
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):485-91. PubMed ID: 18989231
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
[TBL] [Abstract][Full Text] [Related]
24. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
Crommentuyn KM; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Antivir Ther; 2004 Oct; 9(5):779-85. PubMed ID: 15535416
[TBL] [Abstract][Full Text] [Related]
25. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
[TBL] [Abstract][Full Text] [Related]
26. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
[TBL] [Abstract][Full Text] [Related]
27. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.
Yang J; Nikanjam M; Best BM; Pinto J; Chadwick EG; Daar ES; Havens PL; Rakhmanina N; Capparelli EV
J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
29. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
Hartkoorn RC; Kwan WS; Shallcross V; Chaikan A; Liptrott N; Egan D; Sora ES; James CE; Gibbons S; Bray PG; Back DJ; Khoo SH; Owen A
Pharmacogenet Genomics; 2010 Feb; 20(2):112-20. PubMed ID: 20051929
[TBL] [Abstract][Full Text] [Related]
30. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
Huang F; Scholl P; Huang DB; MacGregor TR; Vinisko R; Castles MA; Berger F; Robinson P
J Clin Pharmacol; 2011 Jul; 51(7):1061-70. PubMed ID: 20705951
[TBL] [Abstract][Full Text] [Related]
31. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
[TBL] [Abstract][Full Text] [Related]
32. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.
Micheli V; Regazzi M; Dickinson L; Meraviglia P; Villani P; Khoo SH; Viganò P; Cordier L; Cusato M; Duca P; Orlando G; Rizzardini G; Back DJ; Cargnel A
Ther Drug Monit; 2008 Jun; 30(3):306-13. PubMed ID: 18520602
[TBL] [Abstract][Full Text] [Related]
33. Lopinavir/ritonavir population pharmacokinetics in neonates and infants.
Urien S; Firtion G; Anderson ST; Hirt D; Solas C; Peytavin G; Faye A; Thuret I; Leprevost M; Giraud C; Lyall H; Khoo S; Blanche S; Tréluyer JM
Br J Clin Pharmacol; 2011 Jun; 71(6):956-60. PubMed ID: 21564164
[TBL] [Abstract][Full Text] [Related]
34. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
Molina JM; Podsadecki TJ; Johnson MA; Wilkin A; Domingo P; Myers R; Hairrell JM; Rode RA; King MS; Hanna GJ
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1505-14. PubMed ID: 18160008
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.
Bruce RD; Altice FL; Moody DE; Morse GD; Andrews L; Lin SN; Fang WB; Ma Q; Friedland GH
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):511-4. PubMed ID: 20672450
[TBL] [Abstract][Full Text] [Related]
36. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.
Berno G; Zaccarelli M; Gori C; Tempestilli M; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
BMC Med Genet; 2014 Jul; 15():76. PubMed ID: 24986243
[TBL] [Abstract][Full Text] [Related]
37. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
38. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
[TBL] [Abstract][Full Text] [Related]
39. Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.
Gutiérrez F; Padilla S; Masiá M; Navarro A; Gallego J; Hernández I; Ramos JM; Martin-Hidalgo A
Antivir Ther; 2004 Feb; 9(1):105-13. PubMed ID: 15040542
[TBL] [Abstract][Full Text] [Related]
40. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.
Schipani A; Egan D; Dickinson L; Davies G; Boffito M; Youle M; Khoo SH; Back DJ; Owen A
Antivir Ther; 2012; 17(5):861-8. PubMed ID: 22477766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
